The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant – a retrospective study
Nahid Rashid
Department of Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO, USA
Search for more papers by this authorMichael Slade
Department of Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO, USA
Search for more papers by this authorRamzi Abboud
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorFeng Gao
Division of Public Health Sciences, Department of Surgery, Washington University, Saint Louis, MO, USA
Search for more papers by this authorJohn F. DiPersio
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorPeter Westervelt
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorGeoffrey Uy
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorKeith Stockerl-Goldstein
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorRizwan Romee
Department of Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Search for more papers by this authorCorresponding Author
Mark A. Schroeder
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Correspondence
Mark A. Schroeder MD, Division of Oncology, Washington University School of Medicine, Campus Box 8007, 660 S. Euclid Avenue, St. Louis MO 63110, USA.
Tel.: 314-454-8306;
fax: 314-454-7551;
e-mail: [email protected]
Search for more papers by this authorNahid Rashid
Department of Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO, USA
Search for more papers by this authorMichael Slade
Department of Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO, USA
Search for more papers by this authorRamzi Abboud
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorFeng Gao
Division of Public Health Sciences, Department of Surgery, Washington University, Saint Louis, MO, USA
Search for more papers by this authorJohn F. DiPersio
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorPeter Westervelt
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorGeoffrey Uy
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorKeith Stockerl-Goldstein
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Search for more papers by this authorRizwan Romee
Department of Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Search for more papers by this authorCorresponding Author
Mark A. Schroeder
Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA
Correspondence
Mark A. Schroeder MD, Division of Oncology, Washington University School of Medicine, Campus Box 8007, 660 S. Euclid Avenue, St. Louis MO 63110, USA.
Tel.: 314-454-8306;
fax: 314-454-7551;
e-mail: [email protected]
Search for more papers by this authorSummary
We retrospectively analyzed outcomes in patients with acute myeloid leukemia (AML) receiving reduced-intensity conditioning (RIC) hematopoietic stem cell transplants (HCT) from a peripheral blood (PB) source. We identified 46 haploidentical HCT (haplo), 59 matched unrelated donor HCT (MUD), and 40 matched related donor HCT (SIB) patients at a single institution. Haplo had improved overall survival (OS) when compared to MUD, HR 2.03 (P = 0.01) but not SIB, HR 1.17 (P = 0.61). There were no differences in relapse rates or treatment-related mortality (TRM). Haplo had higher rates of acute graft-versus-host disease (GVHD) grade II–IV at day 180 than MUD (44% vs. 25%, P = 0.03) and SIB (44% vs. 13% P < 0.01). Rates of acute GVHD III–IV and chronic GVHD were similar among the groups. Haplo had slower engraftment rates compared to MUD with neutrophil engraftment at 87% vs. 93%, (P < 0.01) and platelet engraftment at 59% vs. 86%, (P < 0.01) at 28 days. Although patients receiving haplo had higher acute GVHD II–IV and slower engraftment, they did not have increased TRM. These data may suggest that patients receiving haplo have improved OS compared to MUD for AML patients receiving RIC transplants. This should be confirmed using a larger cohort.
Conflicts of interest
The authors have declared no conflicts of interest.
Supporting Information
| Filename | Description |
|---|---|
| tri13659-sup-0001-FigS1.docxWord document, 72.1 KB | Figure S1. Cumulative incidence of GVHD. |
| tri13659-sup-0002-FigS2.docxWord document, 127.4 KB | Figure S2. Acute GVHD and relapse free survival. |
| tri13659-sup-0003-TableS1.xlsxapplication/excel, 12.2 KB | Table S1. Analysis of relapse. |
| tri13659-sup-0004-TableS2.xlsxapplication/excel, 8.8 KB | Table S2. Chronic GVHD grade by donor type. |
| tri13659-sup-0005-AppendixS1.docxWord document, 11.7 KB | Appendix S1. Cause of death. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Scott B, Pasquini M, Logan B. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017; 35: 1154.
- 2Aoudjhane M, Labopin M, Gorin N, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimens in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukemia: a retrospective study from the Acute Leukemia Working Party for the European group for Blood and Marrow Transplantation. Leukemia 2005; 19: 2304.
- 3Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033.
- 4Ghosh N, Karmali R, Rocha V, et al. Reduced-Intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol 2016; 34: 3141.
- 5Luo Y, Xiao H, Lai X, et al. T- cell-replete haploidentical HCT with low dose anti-T-lymphocyte globulin compared with matched sibling HCT and unrelated HCT. Blood 2014; 124: 2735.
- 6Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011; 17: 821.
- 7Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol 2017; 35: 3002.
- 8 Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood-stem cell stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074.
- 9Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
- 10Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015; 21: 389.
- 11Armand P, Kim HT, Zhang M-J. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a center for international blood and bone marrow transplant research study. Biol Blood Marrow Transplant 2012; 18: 280.
- 12Armand P, Kim HT, Logan BR. Validation and refinement of the disease risk index for allogeneic cell transplantation. Blood J 2014; 123: 3664.
- 13Sorror M, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912.
- 14Bashey A, Zhang X, Jackson K. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant 2016; 22: 125.
- 15Santoro N, Labopin M, Giannotti F. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol 2018; 11: 55. https://doi.org/10.1186/s13045-018-0598-0.
- 16Waller EK, Giver CR, Rosenthal H, et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis 2004; 33: 233.
- 17Kanarkry C, O’Donnell PV, Furlong T. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32: 3497.
- 18Bryant A, Mallick R, Huebsch L, et al. Low-dose antithymocyte globulin for graft-versus-host-disease prophylaxis in matched unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplantation 2017; 23: 2096.
- 19Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell-replete peripheral blood stem cells and myeloablative conditioning in patients with high risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859.
- 20Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015; 21: 1299.
